Is Hepatitis B entering the era of personalised medicine?

A.ThompsonA.Thompson
M.DouglasM.Douglas
BulletArticle
Infectious Diseases Liver disease & HCC
共享以下内容：
复制链接
Is Hepatitis B entering the era of personalised medicine_thumbnail

New cure strategies for Hepatitis B are in development. Emerging data suggests a key role for biomarkers to identify subsets of people living with Hepatitis B who are most likely to respond to treatment. In this webinar, we discussed recent advances in Hepatitis B biomarker development, and how these tools can be used to personalise the management of people living with Hepatitis B.
 

共享以下内容：
复制链接

有关同一主题的更多信息

AMILI brings ‘precision gut microbiomics’ to Southeast Asia

PIVKA-II drives early detection of HCC in Vietnam

推荐主题

定序RED 2020Rare Diseases
下次阅读
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
3 steps to mitigate the impact of interference
  • Clinician Engagement, Coagulation, Disease Area, Management
3 steps to mitigate the impact of interference
A guide to balancing quality, speed and cost
  • Operational Excellence, Operations
A guide to balancing quality, speed and cost
Scroll to Top